These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. [Indications, contra-indications and dosage of cardiac glycosides controlled by plasma levels in the aged]. Hötter GJ Z Gerontol; 1987; 20(1):8-12. PubMed ID: 3577317 [TBL] [Abstract][Full Text] [Related]
25. [Therapy of chronic cardiac insufficiency with cardiac glycosides]. Bonelli J Wien Med Wochenschr; 1982 Oct; 132(19):442-9. PubMed ID: 7179995 [No Abstract] [Full Text] [Related]
26. [Serum glycoside level in old age. Problems of course control in glycoside therapy]. Schwarzfischer VP Fortschr Med; 1976 May; 94(14):841-6. PubMed ID: 818003 [TBL] [Abstract][Full Text] [Related]
27. [Clinical study of meproscillarin rates of inactivation and persistence, bioavailability and maintenance dose]. Herken H; Brandes J Arzneimittelforschung; 1978; 28(3a):557-60. PubMed ID: 580590 [TBL] [Abstract][Full Text] [Related]
28. [Pharmacokinetic studies on helveticosol acetonide in man]. Zielske F; Dovidat H; Betzien G; Voigtländer W Arzneimittelforschung; 1971 Apr; 21(4):566-71. PubMed ID: 5108163 [No Abstract] [Full Text] [Related]
29. [Recent aspects of therapy with cardiac glycosides]. Bayer O; Jost F Dtsch Med J; 1970 May; 21(10):675-6 passim. PubMed ID: 5523167 [No Abstract] [Full Text] [Related]
30. [Cardiac glycoside therapy]. Born H Folia Clin Int (Barc); 1969 Nov; 17(11):534-45. PubMed ID: 5803723 [No Abstract] [Full Text] [Related]
31. [Value and indications for the determination of cardiac glycoside levels]. Larbig D Fortschr Med; 1982 Oct; 100(38):1749-52. PubMed ID: 7141374 [No Abstract] [Full Text] [Related]
32. [Elimination of cardiac glycosides by hemofiltration]. Kramer P; Matthias C; Matthaei D; Scheler F Verh Dtsch Ges Inn Med; 1977 Apr 17-21; 83():1618-21. PubMed ID: 611892 [No Abstract] [Full Text] [Related]
33. [On the blood level and secretion of radioactively labeled cardiac glycosides following intraduodenal application in the cat]. Lahrtz H; Sattler RW; van Zwieten PA Z Gesamte Exp Med Einschl Exp Chir; 1968; 148(3):210-22. PubMed ID: 5728874 [No Abstract] [Full Text] [Related]
34. Tissue distribution, metabolism and elimination of cardiac glycosides. van Zwieten PA Ger Med Mon; 1968 Jul; 13(7):346-9. PubMed ID: 4879650 [No Abstract] [Full Text] [Related]
35. [Behavior of urinary secretion and plasma levels of various cardiac glycosides at the time of hospital admission]. Ochs HR; Bodem G; Otten H; Meyer R; Baur MP Verh Dtsch Ges Inn Med; 1978; (84):749-52. PubMed ID: 742116 [No Abstract] [Full Text] [Related]
36. [Studies on the pharmacokinetics of meproscillarin (author's transl)]. Belz GG; Belz G Arzneimittelforschung; 1978; 28(3a):535-9. PubMed ID: 580584 [No Abstract] [Full Text] [Related]
37. [Possibilities and problems or long-term therapy using cardiac glycosides]. Gillmann H Z Gesamte Inn Med; 1973 Feb; 28(3):41-5 passim. PubMed ID: 4633782 [No Abstract] [Full Text] [Related]
38. [Therapeutic equivalence and inequivalence of chemically identical substances using cardiac glycosides for an example (author's transpl)]. Rietbrock N Arzneimittelforschung; 1976; 26(1A):135-46. PubMed ID: 947193 [TBL] [Abstract][Full Text] [Related]
39. Receptor kinetics and concentration-effect relation of cardiac glycosides. Schaumann W; Kaufmann B Wien Klin Wochenschr Suppl; 1992; 191():52-5. PubMed ID: 1324545 [TBL] [Abstract][Full Text] [Related]